Biopharma | April 14, 2026
Gennova CEO Dr Sanjay Singh sees strong innovation momentum for India’s biopharma sector
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
With the expansion, the hospital’s total bed capacity will rise from 380 to 539 beds
The centre offers a full spectrum of FDA-approved services, including physiotherapy, occupational therapy, speech and language therapy, and aqua therapy
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
This event will bring together global stakeholders to explore India’s growing capabilities in pharma and biopharma innovation, research, and manufacturing
No adverse events reported; recall involves 5 mg 500-count bottles in the US market
Integrated multidisciplinary model positions Hyderabad as a growing referral hub for advanced pediatric care
MoU aims to strengthen academia-industry collaboration in healthcare research and innovation
The two-day conference and exhibition features discussions on policy frameworks, AI-led drug discovery, next-generation technologies, and global competitiveness
Subscribe To Our Newsletter & Stay Updated
